DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.

Category Primary study
ConferenceASCO MEETING ABSTRACTS
Year 2025
This article has no abstract
Epistemonikos ID: b79946fcc87ce73dba6a1e30cf55fbe1d2d1c865
First added on: May 16, 2026